Skip to main content

Advertisement

SpringerLink
Log in

Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?

  • Letter to the editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Miller PD (2011) The kidney and bisphosphonates. Bone 49:77–81

    Article  CAS  PubMed  Google Scholar 

  2. Liu WC, Yen JF, Lang CL, Yan MT, Lu KC (2013) Bisphosphonates in CKD patients with low bone mineral density. Scientific World Journal 837573:1–11

    Google Scholar 

  3. Markowitz GS, Appel GB, Fine PL et al (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164–1172

    CAS  PubMed  Google Scholar 

  4. Balla J (2005) The issue of renal safety of zoledronic acid from a nephrologist’s point of view. Oncologist 10:306–308

    Article  PubMed  Google Scholar 

  5. Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186–190

    Article  PubMed  Google Scholar 

  6. Beigel AE, Rienhoff E, Olbricht CJ (1995) Removal of clodronate by haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant 10:2266–2268

    CAS  PubMed  Google Scholar 

  7. Saha H, Castren-Kortekangas P, Ojanen S, Juhakoski A, Tuominen J, Tokola O, Pasternack A (1994) Pharmacokinetics of clodronate in renal failure. J Bone Miner Res 9:1953–1958

    Article  CAS  PubMed  Google Scholar 

  8. Bergner R, Dill K, Boerner D, Uppenkamp M (2002) Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 17:1281–1285

    Article  CAS  PubMed  Google Scholar 

  9. Buttazzoni M, Rosa Diez GJ, Jager V, Crucelegui MS, Algranati SL, Plantalech L (2006) Elimination and clearance of pamidronate by haemodialysis. Nephrology (Carlton) 1:197–200

    Article  Google Scholar 

  10. Conte P, Guarneri V (2004) Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9(4):28–37

    Article  CAS  PubMed  Google Scholar 

  11. Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M (2006) Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29:534–540

    Article  CAS  PubMed  Google Scholar 

  12. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K, American Society of Clinical Oncology (2007) (2007) Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464–2472

    Article  CAS  PubMed  Google Scholar 

  13. Bragalone DL (2013) Drug information hand book of oncology, 11th edn. Lexicomp, Inc, Hudson Ohio, pp 305–306

    Google Scholar 

  14. Von Moos R (2005) Bisphosphonate treatment recommendations for oncologists. Oncologist 10:19–24

    Article  Google Scholar 

Download references

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Tepecik Education and Research Hospital, Gaziler Caddesi No: 468, 35170, Konak, Izmir, Turkey

    Fatos Dilan Koseoglu

  2. Department of Medical Oncology, Medical Park Hospital, Izmir University, Yeni Girne Bulvarı 1825 Sok. No:12, Karsiyaka, Izmir, Turkey

    Cagatay Arslan

Authors
  1. Fatos Dilan Koseoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cagatay Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fatos Dilan Koseoglu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koseoglu, F.D., Arslan, C. Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?. Support Care Cancer 23, 1489–1491 (2015). https://doi.org/10.1007/s00520-015-2672-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-2672-2

Keywords

Search

Navigation